Magic mushroom compound may turn back the biological clock — a trial investigates

NCT ID NCT07719088

Not yet recruiting Knowledge-focused Sponsor: Charles Raison Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study tests whether psilocybin, the active compound in magic mushrooms, can influence biological markers of aging in healthy adults aged 60 to 80. Participants receive one, two, or three doses of 25 mg psilocybin or join a wait-list group. Researchers will measure changes in epigenetic clocks, telomere length, and sense of purpose over 12 months to see if the drug might slow or reverse aspects of aging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a single 25 mg capsule of psilocybin, given one, two, or three times at four-week intervals
What this could lead to: If psilocybin measurably slows or reverses biological aging markers, it could open a new path for healthy-aging interventions.
What could go wrong: This is a small Phase 1 dose-ranging trial, not designed to prove anti-aging effects. Psilocybin can cause intense psychological experiences and may not be safe for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGING BIOMARKERS OF AGING LONGEVITY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Vail Health Behavioral Health

Edwards, Colorado, 81632, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.